Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2011, Article ID 565060, 4 pages
http://dx.doi.org/10.4061/2011/565060
Review Article

Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC

1Division of General Surgery, University of Calgary, AB, Canada T2N 1N4
2Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
3Department of Surgery, Foothills Medical Centre, 1403-29th Street NW, Calgary, AB, Canada T2N 2T9

Received 17 January 2011; Accepted 15 March 2011

Academic Editor: Ryosuke Tateishi

Copyright © 2011 Gitonga Munene et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. X. Bosch, J. Ribes, M. Díaz, and R. Cléries, “Primary liver cancer: worldwide incidence and trends,” Gastroenterology, vol. 127, pp. S5–S16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. H. B. El-Serag and A. C. Mason, “Rising incidence of hepatocellular carcinoma in the United States,” New England Journal of Medicine, vol. 340, no. 10, pp. 745–750, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Dixon, E. Abdalla, R. E. Schwarz, and J. N. Vauthey, “AHPBA/SSO/SSAT sponsored consensus conference on multidisciplinary treatment of hepatocellular carcinoma,” HPB, vol. 12, no. 5, pp. 287–288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. N. Vauthey, E. Dixon, E. K. Abdalla et al., “Pretreatment assessment of hepatocellular carcinoma: expert consensus statement,” HPB, vol. 12, no. 5, pp. 289–299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Ichikawa, K. Saito, N. Yoshioka et al., “Detection and characterization of focal liver lesions: a Japanese Phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease,” Investigative Radiology, vol. 45, no. 3, pp. 133–141, 2010. View at Publisher · View at Google Scholar
  6. H. Watanabe, M. Kanematsu, S. Goshima et al., “Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted mr imaging—preliminary observations,” Radiology, vol. 259, no. 1, pp. 142–150, 2011. View at Publisher · View at Google Scholar
  7. M. Makuuchi, B. L. Thai, K. Takayasu et al., “Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report,” Surgery, vol. 107, no. 5, pp. 521–527, 1990. View at Google Scholar · View at Scopus
  8. D. Ribero, E. K. Abdalla, D. C. Madoff, M. Donadon, E. M. Loyer, and J. N. Vauthey, “Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome,” British Journal of Surgery, vol. 94, no. 11, pp. 1386–1394, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Kubota, M. Makuuchi, K. Kusaka et al., “Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors,” Hepatology, vol. 26, no. 5, pp. 1176–1181, 1997. View at Google Scholar · View at Scopus
  10. Y. Kishi, E. K. Abdalla, Y. S. Chun et al., “Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry,” Annals of Surgery, vol. 250, no. 4, pp. 540–547, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Aoki, H. Imamura, K. Hasegawa et al., “Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma,” Archives of Surgery, vol. 139, no. 7, pp. 766–774, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. S. H. Teh, J. Christein, J. Donohue et al., “Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of end-stage liver disease (MELD) score predicts perioperative mortality,” Journal of Gastrointestinal Surgery, vol. 9, no. 9, pp. 1207–1215, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. M. S. Chen, J. Q. Li, Y. Zheng et al., “A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma,” Annals of Surgery, vol. 243, no. 3, pp. 321–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Livraghi, F. Meloni, M. Di Stasi et al., “Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?” Hepatology, vol. 47, no. 1, pp. 82–89, 2008. View at Publisher · View at Google Scholar
  15. W. Jarnagin, W. C. Chapman, S. Curley et al., “Surgical treatment of hepatocellular carcinoma: expert consensus statement,” HPB, vol. 12, no. 5, pp. 302–310, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Shi, R. P. Guo, X. J. Lin et al., “Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial,” Annals of Surgery, vol. 245, no. 1, pp. 36–43, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Ishizawa, K. Hasegawa, T. Aoki et al., “Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma,” Gastroenterology, vol. 134, no. 7, pp. 1908–1916, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. R. T. P. Poon, S. T. Fan, I. O. L. Ng, and J. Wong, “Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal,” Annals of Surgery, vol. 231, no. 4, pp. 544–551, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. S. T. Fan, C. M. Lo, C. L. Liu et al., “Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths,” Annals of Surgery, vol. 229, no. 3, pp. 322–330, 1999. View at Google Scholar · View at Scopus
  20. Y. Inoue, K. Hasegawa, T. Ishizawa et al., “Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma?” Surgery, vol. 145, no. 1, pp. 9–19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Croce, M. Azzola, R. Russo, M. Golia, S. Angelini, and S. Olmi, “Laparoscopic liver tumour resection with the argon beam,” Endoscopic Surgery and Allied Technologies, vol. 2, no. 3-4, pp. 186–188, 1994. View at Google Scholar · View at Scopus
  22. L. Viganò, C. Tayar, A. Laurent, and D. Cherqui, “Laparoscopic liver resection: a systematic review,” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 16, no. 4, pp. 410–421, 2009. View at Publisher · View at Google Scholar
  23. V. Mazzaferro, E. Regalia, R. Doci et al., “Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis,” New England Journal of Medicine, vol. 334, no. 11, pp. 693–699, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Y. Yao, L. Ferrell, N. M. Bass et al., “Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival,” Hepatology, vol. 33, no. 6, pp. 1394–1403, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Bharat, D. B. Brown, J. S. Crippin et al., “Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival,” Journal of the American College of Surgeons, vol. 203, no. 4, pp. 411–420, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Adam, D. Azoulay, D. Castaing et al., “Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?” Annals of Surgery, vol. 238, no. 4, pp. 508–519, 2003. View at Google Scholar · View at Scopus
  27. W. C. Chapman, M. B. Majella Doyle, J. E. Stuart et al., “Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation,” Annals of Surgery, vol. 248, no. 4, pp. 617–624, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Mazzaferro, C. Battiston, S. Perrone et al., “Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study,” Annals of Surgery, vol. 240, no. 5, pp. 900–909, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Y. Yao, M. Kinkhabwala, J. M. LaBerge et al., “The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma,” American Journal of Transplantation, vol. 5, no. 4 I, pp. 795–804, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. R. E. Schwarz, G. K. Abou-Alfa, J. F. Geschwind, S. Krishnan, R. Salem, and A. P. Venook, “Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement,” HPB, vol. 12, no. 5, pp. 313–320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. J. M. Llovet, M. I. Real, X. Montaña et al., “Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial,” Lancet, vol. 359, no. 9319, pp. 1734–1739, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. C. M. Lo, H. Ngan, W. K. Tso et al., “Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma,” Hepatology, vol. 35, no. 5, pp. 1164–1171, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Salem, R. J. Lewandowski, M. F. Mulcahy et al., “Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes,” Gastroenterology, vol. 138, no. 1, pp. 52–64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. L. M. Kulik, B. Atassi, L. Van Holsbeeck et al., “Yttrium-90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation,” Journal of Surgical Oncology, vol. 94, no. 7, pp. 572–586, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. L. M. Kulik, B. I. Carr, M. F. Mulcahy et al., “Safety and efficacy of Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis,” Hepatology, vol. 47, no. 1, pp. 71–81, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Krishnan, L. A. Dawson, J. Seong et al., “Radiotherapy for hepatocellular carcinoma: an overview,” Annals of Surgical Oncology, vol. 15, no. 4, pp. 1015–1024, 2008. View at Publisher · View at Google Scholar · View at Scopus